Related references
Note: Only part of the references are listed.Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors
Giovanni Caocci et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2020)
The role of bosutinib in the treatment of chronic myeloid leukemia
Carlo Gambacorti-Passerini et al.
FUTURE ONCOLOGY (2020)
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
Claudia Vener et al.
BLOOD ADVANCES (2020)
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Andreas Hochhaus et al.
LEUKEMIA (2020)
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
Giovanni Caocci et al.
ANNALS OF HEMATOLOGY (2019)
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline
Monica Crugnola et al.
ANNALS OF HEMATOLOGY (2019)
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy
Mario Tiribelli et al.
ANNALS OF HEMATOLOGY (2019)
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment
Massimo Breccia et al.
ANNALS OF HEMATOLOGY (2018)
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
H. J. Khoury et al.
ANNALS OF ONCOLOGY (2018)
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Bruno C. Medeiros et al.
BLOOD REVIEWS (2018)
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?
Roberto Latagliata et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
Jorge E. Cortes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
Susanne Isfort et al.
JOURNAL OF BLOOD MEDICINE (2018)
Second line small molecule therapy options for treating chronic myeloid leukemia
Matteo Molica et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
The safety of Bosutinib for the treatment of chronic myeloid leukemia
Jee Hyun Kong et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J. L. Steegmann et al.
LEUKEMIA (2016)
Frontline Dasatinib Treatment in a Real-Life Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
Roberto Latagliata et al.
NEOPLASIA (2016)
Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
Elias Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
Expanding Nilotinib Access in Clinical Trials (ENACT) An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphi Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase
Franck E. Nicolini et al.
CANCER (2012)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib
Massimo Breccia et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib
Roberto Latagliata et al.
LEUKEMIA RESEARCH (2011)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories
M. C. Mueller et al.
LEUKEMIA (2008)
Share Paper
